MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xcrm.2026.103080

Медицинская библиотека · Cell reports. Medicine · 2026

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

Van Renne Nicolaas, Agostinetto Elisa, Joaquín García Andrea, Morfouace Marie, Możejko Marcin, Denis Zoë, Déglise Sophie, Bodenmiller Bernd, Hong Henoch S, Venet David, Carausu Marcela, Liechti Robin, Tissot Stéphanie, Rusakiewicz Sylvie, Rediti Mattia, Catteau Xavier, Schulz Daniel, Loirat Delphine, Herrero Saboya Daniel, Aftimos Philippe, Benelli Matteo, Guerrero-Zotano Angel L, Gombos Andrea, Wildiers Hans, Van Dinter Jip, Sickinghe Ariane, Penel Nicolas, Goeminne Jean-Charles, Oliveira Júlio, Brasiuniene Birute, Romano Emanuela, Balko Justin M, Kok Marleen, Szczurek Ewa, Sotiriou Christos, Buisseret Laurence

СтатьяПеревод в очереди

Аннотация

No validated biomarkers beyond PD-L1 currently guide immune checkpoint inhibition (ICI) in advanced triple-negative breast cancer (TNBC), and how tumors remodel their microenvironment in response to ICI remains incompletely understood. We perform a temporal analysis of patients with advanced TNBC treated with chemo-immunotherapy in the SYNERGY trial (NCT03616886; n = 84) and the EORTC-1553-SPECTA initiative (NCT02834884; n = 38) using RNA sequencing, whole-exome sequencing, multiplex immunofluorescence, and imaging mass cytometry. A transcriptomic progression-free survival (PFS)-based risk signature stratifies outcomes and is validated across ICI-treated cohorts, while showing context-dependent behavior in non-ICI settings. Favorable outcomes are associated with immune-enriched tumors with organized lymphoid architecture, while poor outcomes are linked to fibrotic, angiogenic microenvironments with frequent PI3K alterations. Upon treatment, early progression was characterized by fibrovascular remodeling, macrophage expansion, and upregulation of alternative immunosuppressive mediators. These findings establish fibrovascular and myeloid reprogramming as a coordinated resistance program, identify actionable therapeutic targets, and support microenvironment stratification in future ICI-based trials.

Для цитирования: Van Renne Nicolaas, Agostinetto Elisa, Joaquín García Andrea, Morfouace Marie, Możejko Marcin, Denis Zoë, Déglise Sophie, Bodenmiller Bernd, Hong Henoch S, Venet David, Carausu Marcela, Liechti Robin, Tissot Stéphanie, Rusakiewicz Sylvie, Rediti Mattia, Catteau Xavier, Schulz Daniel, Loirat Delphine, Herrero Saboya Daniel, Aftimos Philippe, Benelli Matteo, Guerrero-Zotano Angel L, Gombos Andrea, Wildiers Hans, Van Dinter Jip, Sickinghe Ariane, Penel Nicolas, Goeminne Jean-Charles, Oliveira Júlio, Brasiuniene Birute, Romano Emanuela, Balko Justin M, Kok Marleen, Szczurek Ewa, Sotiriou Christos, Buisseret Laurence. A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.. Cell reports. Medicine. 2026. DOI: 10.1016/j.xcrm.2026.103080.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.